Braveheart Bio Inc. (BRVE)
NasdaqGM: BRVE
· Real-Time Price · USD
26.75
-0.91 (-3.29%)
At close: Aug 18, 2026, 3:59 PM
Braveheart Bio Inc. (BRVE) Stock Price, Analysis & Data
-3.29% (1D)
| Bid | n/a |
| Market Cap | 1.89B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -80.23M |
| Beta | n/a |
| EPS (ttm) | -1.87 |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| P/B (ttm) | -10.40 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | n/a |
| Volume | 214,644 |
| Avg. Volume (20D) | 799,555 |
| Open | 27.64 |
| Previous Close | 27.66 |
| Day's Range | 25.76 - 28.50 |
| 52-Week Range | 24.61 - 32.00 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About BRVE
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California....
Industry Biotechnology
Sector Healthcare
IPO Date Aug 6, 2026
Employees 30
Stock Exchange NasdaqGM
Ticker Symbol BRVE
Website https://www.braveheart.bio
Financial Performance
In 2025, Braveheart Bio's revenue was 0, an increase of undefined% compared to the previous year's n/a. Earnings were -66.05M, an increase of undefined%.
Financial Statements